Satyam Infoway Ltd-(Nasdaq:SIFY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Satyam Infoway Ltd-(Nasdaq:SIFY)

SIFY 11.40

-5.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mohan Marette who wrote (1229)	3/17/2000 9:05:00 AM
From: Mohan Marette	Read Replies (1) of 1471

OT After software, it's pharma ADRs Dr.Reddy's drreddys.com Ranbaxy ranbaxy.com Cheminor Drugs cheminor.com Nicholas Piramal nicholaspiramal.com Dr. Reddy's Laboratories has slated a $ 150 million American Depository Share issue. The report in a financial daily also mentions plans of Ranbaxy and Nicholas Piramal for ADR issues. DRL is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has grown from being a bulk drug company to a respected formulation based company. It has products such as omeprazole (gastro-intestinal), ciprolet (anti-infective) Nise (pain and fever), Enam (cardiovascular) etc. DRL has three new original molecules in its research pipeline. One is an anti-cancer compound, another was a Cox II inhibitor (anti-pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future. Its sister concern Cheminor has filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline. The company has set a target to file three to five ANDAs every year and have already received approval for ranitidine (75 mg), the anti-ulcerant omeprazole and anti-depressant fluoxetine. It is quite possible that the company may have plans to integrate Cheminor with itself before it goes in for an ADR listing. This could enable it to get a better price. The management has already announced that Cheminor will be eventually merged with DRL. March 17, 2000 -Quantum

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next